Table I.
Characteristics of Patients With and Without Diabetes by Study and Treatment Group
| Demographic Variable | Val‐MARC | VALOR | VELOCITY | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VAL 160→320 mg | VAL/HCTZ 160/12.5→320/12.5 mg | VAL 80→160 mg | VAL/HCTZ 160/0→ (160/12.5, 160/25 mg) | VAL 80 mg→VAL/HCTZ 160/12.5 mg | VAL 160 mg→VAL/HCTZ 160/25 mg | VAL/HCTZ 160/12.5→160/25 mg | ||||||||
| Diabetes Status | Yes (n=95) | No (n=712) | Yes (n=66) | No (n=740) | Yes (n=26) | No (n=235) | Yes (n=51) | No (n=455) | Yes (n=23) | No (n=195) | Yes (n=30) | No (n=189) | Yes (n=30) | No (n=180) |
| Sex | ||||||||||||||
| Male, No. (%) | 58 (61.1) | 390 (54.8) | 35 (53.0) | 399 (53.9) | 15 (57.7) | 115 (48.9) | 29 (56.9) | 252 (55.4) | 13 (56.5) | 106 (54.4) | 19 (63.3) | 102 (54.0) | 17 (56.7) | 93 (51.7) |
| Race | ||||||||||||||
| White, No. (%) | 57 (60.0) | 497 (69.8) | 41 (62.1) | 505 (68.2) | 24 (92.3) | 219 (93.2) | 45 (88.2) | 428 (94.1) | 17 (73.9) | 135 (69.2) | 17 (56.7) | 132 (69.8) | 15 (50.0) | 120 (66.7) |
| Black, No. (%) | 23 (24.2) | 154 (21.6) | 14 (21.2) | 181 (24.5) | 0 (0.0) | 5 (2.1) | 2 (3.9) | 6 (1.3) | 3 (13.0) | 34 (17.4) | 9 (30.0) | 28 (14.8) | 7 (23.3) | 32 (17.8) |
| Age | ||||||||||||||
| Mean age, y (SD) | 53.3 (10.9) | 50.4 (11.6) | 55.2 (11.3) | 50.7 (11.8) | 63.7 (9.5) | 60.0 (10.7) | 63.6 (9.1) | 60.4 (11.7) | 53.6 (8.4) | 52.0 (11.0) | 53.0 (8.8) | 53.1 (9.0) | 54.1 (7.4) | 52.6 (10.7) |
| ≥65 y, No. (%) | 17 (17.9) | 85 (11.9) | 15 (22.7) | 99 (13.4) | 11 (42.3) | 82 (34.9) | 23 (45.1) | 172 (37.8) | 1 (4.3) | 20 (10.3) | 3 (10.0) | 21 (11.1) | 4 (13.3) | 26 (14.4) |
| Baseline BMI | ||||||||||||||
| No. | 93 | 703 | 66 | 731 | 26 | 229 | 50 | 446 | 23 | 195 | 30 | 189 | 30 | 180 |
| Mean, kg/m2 | 35.1 | 32.3 | 36.5 | 32.4 | 32.0 | 30.1 | 32.1 | 29.9 | 34.6 | 31.7 | 35.4 | 32.3 | 33.6 | 32.3 |
| Baseline SBP | ||||||||||||||
| No. | 95 | 712 | 66 | 740 | 26 | 235 | 51 | 445 | 23 | 195 | 30 | 189 | 30 | 180 |
| Mean, mm Hg (SD) | 167.6 (11.7) | 164.1 (12.5) | 171.4 (10.6)a | 164.5 (13.3) | 167.7 (7.5) | 167.9 (8.1) | 167.1 (6.8) | 167.3 (8.2) | 160.2 (5.6) | 160.8 (7.6) | 162.9 (8.7) | 160.7 (7.8) | 163.6 (8.3) | 160.6 (7.7) |
| Baseline DBP | ||||||||||||||
| No. | 95 | 712 | 66 | 740 | 26 | 235 | 51 | 445 | 23 | 195 | 30 | 189 | 30 | 180 |
| Mean, mm Hg (SD) | 98.0 (10.6) | 100.0 (8.7) | 94.4 (10.1)a | 100.1 (8.4) | 89.2 (10.3) | 93.7 (8.6) | 90.8 (8.6) | 93.8 (9.3) | 95.9 (4.8) | 97.9 (5.5) | 97.3 (3.6) | 98.4 (5.3) | 97.3 (5.7) | 98.3 (5.0) |
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, systolic blood pressure; VAL, valsartan. a P=.03 for VAL 160→320 mg vs VAL/HCTZ 160/12.5→320/12.5 mg. See text for study name expansions.